Method for increasing muscle growth by blocking sirtuin activity
View Patent ↗Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective.
1. A method for increasing skeletal muscle growth in mammals, comprising:
inhibiting the activity of sirtuins in skeletal muscles of a mammal; and
loading the skeletal muscles that have inhibited sirtuin activity,
wherein muscle growth of the loaded skeletal muscles is increased, wherein said sirtuin activity comprises SIRT1 activity and wherein the SIRT1 inhibitor comprises Splitomycin.
2. The method as recited in claim 1 , further comprising:
increasing calorie intake of the mammal while sirtuin activity is inhibited in the skeletal muscles.
3. The method as recited in claim 2 , further comprising:
loading the skeletal muscles of the mammal without aerobic activity;
wherein natural stimulation of sirtuin activity is avoided.
4. The method as recited in claim 1 , further comprising:
administering muscle growth promoting amino acids to the skeletal muscles during a treatment period.
5. The method as recited in claim 1 , further comprising:
delivering a therapeutic dose of a SIRT1 inhibitor to skeletal muscles of a mammal;
wherein the therapeutic dose of SIRT1 inhibitor comprises delivering multiple bolus volumes of the inhibitor with a frequency over a duration that comprises a period of time for treatment; and
wherein SIRT1 inhibition is achieved during the period of time.
6. The method as recited in claim 5 , wherein the therapeutic dose comprises between about 0.025 mg to about 50 mg per kilogram mammal body weight of the SIRT1 inhibitor.
7. The method as recited in claim 5 , wherein the period of time for treatment comprises more than one day.
8. The method as recited in claim 5 :
wherein the period of time for treatment comprises at least a two week period; and
wherein the therapeutic dose comprises between 0.025 mg to 50 mg per kg body weight being delivered per day over the time for treatment.
9. The method of claim 5 , wherein the delivery of said therapeutic dose is performed by intramuscular injection in the body of the mammal.
10. The method of claim 5 , wherein the bolus volumes are delivered by oral or systemic delivery.
11. A method for increasing skeletal muscle growth in mammals, comprising:
inhibiting the activity of SIRT1 in skeletal muscles of a mammal with an inhibitor;
suppressing natural stimulation of SIRT1 production in the mammal; and
loading the skeletal muscles that have inhibited SIRT1 activity,
wherein muscle growth of the loaded skeletal muscles is increased, wherein the SIRT1 inhibitor comprises Splitomycin.
12. The method as recited in claim 11 , further comprising:
administering at least one muscle growth promoting agent to the skeletal muscles during a treatment period.
13. The method as recited in claim 12 , wherein said growth promoting agent comprises at least one amino acid.
14. The method as recited in claim 11 , wherein said suppression of natural stimulation of SIRT1 production comprises:
increasing calorie intake of the mammal; and
loading the skeletal muscles of the mammal without aerobic activity;
wherein natural stimulation of SIRT1 production is suppressed.
15. A method for increasing skeletal muscle growth in mammals, comprising:
inhibiting the activity of SIRT1 in skeletal muscles with an inhibitor in a mammal;
suppressing natural stimulation of SIRT1 production in the mammal;
administering at least one muscle growth promoting agent to the skeletal muscles during a treatment period; and
loading the skeletal muscles with inhibited SIRT1 activity, wherein the SIRT1 inhibitor comprises Splitomycin.
16. The method as recited in claim 15 , wherein the SIRT1 inhibitor comprises Splitomycin of a therapeutic dose of 25 mg per kg body weight.
17. The method as recited in claim 15 :
wherein the treatment period comprises at least a two week period; and
wherein the SIRT1 inhibitor comprises a dose of between 0.25 mg to 50 mg per kg body weight being delivered per day over the treatment period.